Side-by-side · Research reference
GHRP-6vsGlutathione
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1HUMAN-REVIEWED10/36 cited
BHuman-MechanisticHUMAN-REVIEWED6/39 cited
GHRP-6
Hexapeptide GHRP · Strong appetite stimulant
SQ · Multiple sites · 1–3×/day
Glutathione
Endogenous Tripeptide · Antioxidant
IV · Oral · Inhaled
01Mechanism of Action
Parameter
GHRP-6
Glutathione
Primary target
Ghrelin receptor (GHS-R1a)Bowers 1990
Intracellular redox systems, glutathione peroxidase, glutathione transferase
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002
Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH
Downstream effect
GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002
Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction
Feedback intact?
—
—
Origin
Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990
Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025Hecht 2026
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-6
Glutathione
Frequency
1–3× per day
—
Lower / starter dose
50 mcg per dose
—
Duration
8–12 weeks on / 4 off
—
Reconstitution
Bacteriostatic water
—
Timing
Pre-meal preferred for appetite support
—
Endogenous synthesis
—
Hepatic synthesis ~10 g/day (basal rate)
Tissue-specific; demand-driven upregulation via Nrf2 signaling.
Exogenous oral
—
250–1000 mg/day
Bioavailability limited; gastric hydrolysis reduces systemic uptake.
IV supplementation
—
600–1200 mg (research protocols)
Used in clinical oxidative stress and hepatic detoxification studies.
Precursor strategy
—
N-acetylcysteine (NAC) 600–1200 mg/day
Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.
04Side Effects & Safety
Parameter
GHRP-6
Glutathione
Hunger
Pronounced — defining feature vs ipamorelin
—
Cortisol elevation
Mild
—
Prolactin elevation
Mild
—
Injection site reaction
Mild
—
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
—
Oral supplementation
—
GI discomfort, bloating (mild, dose-dependent)
IV administration
—
Rare hypersensitivity, infusion site reaction
Inhalation
—
Bronchospasm risk in asthma (rare)
Tumor metabolism
—
Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026
Absolute Contraindications
GHRP-6
- ·Active malignancy
- ·Pregnancy / breastfeeding
Glutathione
—Relative Contraindications
GHRP-6
- ·Severe insulin resistance (appetite-driven caloric load)
Glutathione
- ·Active malignancy (theoretical cysteine supply risk)Hecht 2026
- ·Severe asthma (inhaled formulations)
05Administration Protocol
Parameter
GHRP-6
Glutathione
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.
2. Injection site
SQ — abdomen. Rotate sites.
Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.
3. Timing
Pre-meal for appetite support; pre-sleep for GH alignment.
Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.
5. Needle
29–31G, 4–8 mm insulin syringe.
—